Rezpegaldesleukin
Atopic Dermatitis
Key Facts
About Nektar Therapeutics
Nektar Therapeutics is dedicated to developing transformative immunomodulatory therapies that restore immune homeostasis in autoimmune and inflammatory diseases. The company's core strategy leverages a deep understanding of immunology to engineer first-in-class agonists targeting upstream regulatory nodes, specifically the IL-2 and TNFR2 pathways, to expand regulatory T cells. With its lead candidate, rezpegaldesleukin, advancing in multiple Phase 2b trials, a seasoned leadership team, and a proven track record of strategic partnerships, Nektar aims to shift treatment paradigms from broad immunosuppression to targeted immune recalibration.
View full company profileAbout Nektar Therapeutics
Nektar Therapeutics is dedicated to developing transformative immunomodulatory therapies that restore immune homeostasis in autoimmune and inflammatory diseases. The company's core strategy leverages a deep understanding of immunology to engineer first-in-class agonists targeting upstream regulatory nodes, specifically the IL-2 and TNFR2 pathways, to expand regulatory T cells. With its lead candidate, rezpegaldesleukin, advancing in multiple Phase 2b trials, a seasoned leadership team, and a proven track record of strategic partnerships, Nektar aims to shift treatment paradigms from broad immunosuppression to targeted immune recalibration.
View full company profileAbout Nektar Therapeutics
Nektar Therapeutics is dedicated to developing transformative immunomodulatory therapies that restore immune homeostasis in autoimmune and inflammatory diseases. The company's core strategy leverages a deep understanding of immunology to engineer first-in-class agonists targeting upstream regulatory nodes, specifically the IL-2 and TNFR2 pathways, to expand regulatory T cells. With its lead candidate, rezpegaldesleukin, advancing in multiple Phase 2b trials, a seasoned leadership team, and a proven track record of strategic partnerships, Nektar aims to shift treatment paradigms from broad immunosuppression to targeted immune recalibration.
View full company profileTherapeutic Areas
Other Atopic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| HBM7575 (SKB575) | Harbour BioMed | IND Filed |
| ITK inhibitor | Acellera | Pre-clinical |
| Encube-003 | Encube Ethicals | Preclinical |
| ENS-002 (Fermata Derm) | Concerto Biosciences | Pre-clinical |
| Lead Program | MatriSys Bioscience | Phase 1 |
| Atopic Dermatitis Trial | Well Pharma Medical Research | Not Specified |
| MEndoB | Micreos | Pre-clinical |
| Atopic Dermatitis Program | Lxbio Pharmaceuticals | Pre-clinical |
| B244 | AOBiome | Phase 3 |
| CTO1681 | CytoAgents | Pre-clinical |
| DS107 | DS Biopharma | Phase 2 |